An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
The effect of L-deprenyl on neuroleptic-induced parkinsonism was evaluated in eleven patients. No significant improvement was observed during the treatment with L-deprenyl in the overall assessment. Four patients, however, were considered responders as their total scores on the modified version of Neurological Rating Scale decreased by at least 50%. No somatic or mental complications were observed during the study. The pretreatment platelet monoamine oxidase activity of the responders was slightly but not significantly higher than that of the non-responders. The plasma prolactin (PRL) levels of the patients with high pretreatment levels decreased significantly during the administration of L-deprenyl.
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy / Q000201:enzymology; D010627:Phenethylamines / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D012559:Schizophrenia / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D010627:Phenethylamines; D012642:Selegiline; D011388:Prolactin; D008995:Monoamine Oxidase